This is a 6 week, open-label, blinded-rater, randomized, controlled, pilot study designed to
determine the dosing, safety and efficacy of ziprasidone in the treatment of pediatric
bipolar disorder (PBD). In this pilot study we are comparing the efficacy of rapid versus
slow dose titration of ziprasidone in PBD. The investigators hypothesize that subjects on
ziprasidone monotherapy will have a reduction in manic symptoms. Also, the investigators
hypothesize that slower titration of ziprasidone will result in lesser side effects which
will assist in medication compliance as measured by patient report and pill count.
Phase:
Phase 4
Details
Lead Sponsor:
Baylor College of Medicine University of Texas Southwestern Medical Center
Collaborators:
Children's Medical Center Dallas Pfizer Stanley Medical Research Institute